LB Pharmaceuticals

tenant

trial

Glycine to Treat Psychotic Disorders in Children

NCTId NCT00005658

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase 2 · Completed

Enrollment 10

Sponsored by National Institute of Mental Health (NIMH)

Synthesized from structured facts only — each point cited above.

Design & status

Phase

Phase 2

Status

Completed

Enrollment

10

Study type

Interventional

Allocation

—

Model

—

Masking

—

Start

2000-05

Primary completion

—

Eligibility

ALL

Interventions & indications

Drugs

Indications

Schizoaffecitve Disorder Psychotic Disorders Schizophrenia Schizophrenia Psychotic Disorder

Sponsors

National Institute of Mental Health (NIMH)Lead Sponsor

Sites

1 total

Bethesda, United States

Facts & assertions

3 sourced

Enrollment

10

Phase

PHASE2

Status

COMPLETED

relationships

The graph out of here

drug

drug

lead_sponsor

National Institute of Mental Health (NIMH)

company

indication

Schizoaffecitve Disorder

indication

Psychotic Disorders

indication

indication